Ruxolitinib for previously treated idiopathic multicentric Castleman disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests the drug ruxolitinib for people with idiopathic multicentric Castleman disease (iMCD) whose symptoms are not well controlled by standard anti-IL-6 therapy. Ruxolitinib is a pill taken by mouth that may help reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a confirmed diagnosis of iMCD that hasn't responded well enough to anti-IL-6 treatment, or you cannot tolerate it.
- You must have active disease symptoms such as fever, fatigue, night sweats, or abnormal lab results (like low hemoglobin or high C-reactive protein).
- You must be able to swallow pills.
- You cannot be pregnant or nursing, and must agree to use effective birth control if needed.
- You cannot have certain infections, other serious medical conditions, or a history of certain cancers (except some skin cancers or cervical cancer in situ).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called pacritinib for people with KSHV-associated multicentric Castleman disease (MCD) or KSHV-associated inflammatory cytokine syndrome (KICS). It aims to see if the drug can help control symptoms and inflammation caused by these conditions.
This trial tests a drug called ruxolitinib for a rare but serious condition called IEC-HS that can happen after CAR T cell treatment. The goal is to see if ruxolitinib can calm this overactive immune response.
This study looks at how KSHV-associated multicentric Castleman disease naturally progresses over time, without necessarily testing a new treatment. It may help doctors better understand the disease and what changes to watch for, which could guide future care.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
This trial tests a new medicine called VDJ001 for people with idiopathic multicentric Castleman disease (iMCD), a rare condition causing enlarged lymph nodes and symptoms like fever, fatigue, weight loss, and poor appetite. The goal is to see if VDJ001 can help control the disease and improve symptoms.
This trial tests a medication called nintedanib, which may help shrink or control the growth of Castleman disease when surgery isn't possible. It is a pill taken by mouth, and the goal is to see if it can help people with this condition.
Hear when a new Castleman's Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.